Method for predicting efficacy of Anti-vegf drug treatment for exudative age-related macular degeneration

A technology related to macular degeneration, applied in the field of diagnostic agents, can solve problems such as unexplained effects

Inactive Publication Date: 2019-07-16
SANTEN PHARMA CO LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the role of molecules regulating angiogenesis in acquiring resistance to anti-VEGF drugs has not been elucidated

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for predicting efficacy of Anti-vegf drug treatment for exudative age-related macular degeneration
  • Method for predicting efficacy of Anti-vegf drug treatment for exudative age-related macular degeneration
  • Method for predicting efficacy of Anti-vegf drug treatment for exudative age-related macular degeneration

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0095] The following four groups were used as objects, and the correlation between the concentration of biomarker candidate substances in serum and the condition of exudative age-related macular degeneration was studied.

[0096] Group A: control group (10 cases)

[0097] Group B: no treatment group (naive) (13 cases)

[0098] Group C: treatment response group (well response) (20 cases)

[0099] Group D: treatment resistance group (refractory) (14 cases)

[0100] The selection and exclusion criteria for each group are shown in the table below.

[0101] [Table 1]

[0102]

[0103] [Table 2]

[0104]

[0105] Protocol for Immunoassays

[0106] As biomarker candidate substances, 16 proteins that have been suggested to be involved in angiogenesis were selected. Serum was prepared from 10 mL of blood collected from each subject. Concentrations of biomarker candidates in serum samples were determined using the Aushon multiplex immunoassay platform (Aushon BioSystems, Bi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Login to view more

Abstract

Provided are: a method for predicting the efficacy of an anti-VEGF drug treatment for exudative age-related macular degeneration, the method comprising (1) measuring the concentration of at least onemarker protein, selected from the group consisting of TGF-beta, BMP-9, angiopoietin-1, and angiopoietin-2, in blood, plasma, or serum collected from a patient with exudative age-related macular degeneration, and (2) correlating the concentration measured in (1) with the efficacy of the anti-VEGF drug treatment for exudative age-related macular degeneration; and a diagnostic agent for the method.

Description

technical field [0001] This application claims priority based on US Provisional Application No. 62 / 428823, the entire contents of which are hereby incorporated by reference. [0002] The present application relates to methods for predicting the effectiveness of treatment of exudative age-related macular degeneration (wet AMD) with anti-VEGF drugs, or diagnostic agents useful in such methods. Background technique [0003] Age-related macular degeneration (AMD: Age-related Macular Degeneration) is one of the main causes of social blindness in the elderly. Age-related macular degeneration is divided into atrophic age-related macular degeneration with geographic atrophy (atrophy of retinal pigment epithelium and choroidal capillaries), and subretinal or subretinal pigment epithelium with choroidal neovascularization (CNV: Choroidal Neovascularization ) is characterized by exudative age-related macular degeneration. It has been clarified that vascular endothelial growth factor ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68
CPCG01N33/6893G01N2800/164G01N2800/52G01N2333/495G01N2333/51G01N2333/515G01N33/6854G01N33/53G01N2333/475G01N33/6872G01N2800/16G01N33/68
Inventor 柴垣圭一敏森将直冈孝次前田晋吾井上博司
Owner SANTEN PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap